Silony Medical International AG has agreed to acquire Centinel Spine’s Global Fusion Business, merging its spinal fusion products with Centinel’s STALIF Technology Platform. The acquisition will create a comprehensive spinal fusion portfolio for both open and minimally invasive spinal fusion cases, covering occiput to sacrum, posterior, lateral, and anterior approaches. This strategic move is expected to strengthen Silony’s position in the global spinal fusion market and enhance its technological capabilities. The transaction is set to close within 45 days, with the financial terms undisclosed.
Silony Medical International AG (the company), a growing challenger to “big medtech” in the global spinal fusion market, has signed a definitive agreement to acquire Centinel Spine’s Global Fusion Business. This combines Silony’s Verticale® posterior screw & rod fusion System, its Roccia® and Favo® Interbody Fusion (IBF) Systems with the STALIF® Technology Platform to create a first in class occiput to sacrum, posterior, lateral and anterior Spinal Fusion Portfolio for open & minimally invasive spinal fusion cases.
“Adding Centinel’s Fusion Products to Silony’s portfolio significantly strengthens our technological and geographic footprint, without cannibalizing products and sales regions” said Silony CEO Constantin Schoen. “Uniting stand-alone/screw integrated cervical and lumbar solutions with our predominantly posterior capabilities is a logical move, that will further accelerate our global growth”
In addition to technology & geographic reach, Silony will welcome a team of professionals from Centinel Spine whose expertise in the anterior fusion market advances patient care every day. Silony is committed to successful long-term relationships, and we look forward to continuing to work with the established STALIF® distributor, surgeon and hospital partners around the world.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The transaction is expected to close within 45 days. Terms were not disclosed.
Source: BioSpace